Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer (original) (raw)
Liao B-C, Lin C-C, Yang JC-H. First-line management of _EGFR_-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357–69. ArticleCASPubMed Google Scholar
Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71(17):2231–46. ArticleCASPubMed Google Scholar
Metro G, Crinò L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673–82. ArticleCASPubMed Google Scholar
Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817–25. ArticleCASPubMed Google Scholar
Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013;6:135–43. CASPubMed CentralPubMed Google Scholar
Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15–22. ArticleCAS Google Scholar
Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2–8. ArticlePubMed Google Scholar
QIAGEN N.V. QIAGEN submits companion diagnostic to FDA to guide treatment decisions for new investigational lung cancer compound [media release]. 2013. http://www.qiagen.com. Accessed 23 Oct 2013.
QIAGEN N.V. QIAGEN receives FDA approval for therascreen® EGFR RGQ PCR Kit as a companion diagnostic for lung cancer patients [media release]. 2013. http://www.qiagen.com. Accessed 23 Oct 2013.
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702–11. ArticleCASPubMed CentralPubMed Google Scholar
Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–50. ArticleCASPubMed Google Scholar
Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28. ArticleCASPubMed CentralPubMed Google Scholar
Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9(6):1647–56. ArticleCASPubMed Google Scholar
Furuyama K, Harada T, Iwama E, et al. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 2013;104(5):584–9. ArticleCASPubMed Google Scholar
Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589–97. ArticleCASPubMed Google Scholar
Kim Y, Ko J, Cui Z-Y, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784–91. ArticleCASPubMed Google Scholar
Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000–10. CASPubMed CentralPubMed Google Scholar
Kim SM, Kwon O-J, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11(10):2254–64. ArticleCASPubMed Google Scholar
Chen G, Noor A, Kronenberger P, et al. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013;8(3):e59708. ArticleCASPubMed CentralPubMed Google Scholar
Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013;72(6):1213–22. ArticleCASPubMed Google Scholar
Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80–5. ArticleCASPubMed CentralPubMed Google Scholar
Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399–408. ArticleCASPubMed CentralPubMed Google Scholar
Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965–72. ArticleCASPubMed Google Scholar
Gordon MS, Mendelson DS, Gross M, et al. A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409–16. ArticleCASPubMed CentralPubMed Google Scholar
Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).
Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101–9. ArticleCASPubMed Google Scholar
Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34. ArticleCASPubMed Google Scholar
Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051–61. ArticleCASPubMed Google Scholar
Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, and irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract]. J Clin Oncol. 2006;24(18S):2074. Google Scholar
Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539–48. ArticleCASPubMed Google Scholar
Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May-4 Jun 2013; Chicago (IL)).
Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342–50. ArticleCASPubMed Google Scholar
Geater SL, Zhou C, Hu C-P, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May–4 Jun 2013; Chicago (IL)).
Yang JC, Schuler M, Yamamoto N, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer [abstract no. 1252P]. Ann Oncol. 2012;23(Suppl 9):ix410–1. Google Scholar
Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer [abstract no. O03.05 plus slide presentation]. 15th World Conference on Lung Cancer; 27–30 Oct 2013; Sydney.
Mok T, Schuler M, Yamamoto N, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Asian patients with adenocarcinoma of the lung harbouring an epidermal growth factor receptor mutation [abstract no. HO-003]. 5th Asia Pacific Lung Cancer Conference; 26–28 Nov 2012; Fukuoka.
Yamamoto N, Schuler M, O’Byrne K, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harbouring an EGFR mutation [abstract no. PLS-6]. Ann Oncol. 2012;23(Suppl 11):xi8. Google Scholar
Schuler M, Yang JC-H, Sequist LV, et al. Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease [abstract no. MO07.13 plus slide presentation]. 15th World Conference on Lung Cancer; 27–30 Oct 2013; Sydney.
Yang JC-H, Sequist LV, O’Byrne KJ, et al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib [abstract no. 895]. Eur J Cancer. 2013;49(Suppl 2):S190 (plus poster presented at European Cancer Congress 2013; 27 Sep–1 Oct 2013; Amsterdam).
Yang JC-H, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729–36. ArticleCASPubMed Google Scholar
Lacouture ME, Schadendorf D, Chu C-YC, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):721–8. ArticleCASPubMed Google Scholar
Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. Ann Oncol. 2012;23(Suppl 9):ix174. Google Scholar
Boehringer Ingelheim Pharmaceuticals. LUX-Lung 8: a phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy [ClinicalTrials.gov identifier NCT01523587]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01523587. Accessed 21 Oct 2013.
Boehringer Ingelheim Pharmaceuticals. LUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung [ClinicalTrials.gov identifier NCT01466660]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01466660. Accessed 21 Oct 2013.
Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155–61. ArticlePubMed Google Scholar
Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23(Suppl 9):ix401. Google Scholar
Boehringer Ingelheim Pharmaceuticals. Trial of BIBW 2992 (afatinib) + cetuximab in non-small cell lung cancer [ClinicalTrials.gov identifier NCT01090011]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01090011. Accessed 22 Oct 2013.
Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303–6. ArticleCASPubMed Google Scholar
De Grevè J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–7. ArticlePubMed Google Scholar
Boehringer Ingelheim Pharmaceuticals. LUX-Breast 2; afatinib in HER2 (human epidermal growth factor receptor)-treatment failures [ClinicalTrials.gov identifier NCT01271725]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01271725. Accessed 23 Oct 2013.
Boehringer Ingelheim Pharmaceuticals. LUX-Breast 3; afatinib alone or in combination with vinorelbine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer suffering from brain metastases [ClinicalTrials.gov identifier NCT01441596]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01441596. Accessed 23 Oct 2013.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 1: a phase III trial of afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01345682]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01345682. Accessed 23 Oct 2013.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 2: a phase III trial of afatinib (BIBW 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy [ClinicalTrials.gov identifier NCT01345669]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01345669. Accessed 23 Oct 2013.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 3: afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01856478]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01856478. Accessed 23 Oct 2013.